Latest Tax Credits News

Breville Group Limited has announced a fully franked ordinary dividend of AUD 0.19 per share for the six months ending December 2025, signaling steady returns for shareholders.

Insurance Australia Group Limited has announced a quarterly dividend of AUD 1.6241 per security for its Capital Notes, payable mid-March 2026, reflecting a steady 6.5141% annualised distribution rate.

Insurance Australia Group Limited has announced a fully franked interim dividend of AUD 0.12 per share for the half-year ending December 2025, alongside a dividend reinvestment plan with no discount.

Evolution Mining Limited has announced a fully franked ordinary dividend of AUD 0.20 per share for the half-year ending December 2025, accompanied by a Dividend Reinvestment Plan with no discount.

AGL Energy Limited has announced a fully franked ordinary dividend of AUD 0.24 per share for the six months ending December 2025, payable in March 2026. This dividend reflects the company’s steady financial footing amid ongoing market challenges.

SGH Limited has announced a fully franked ordinary dividend of AUD 0.32 per share for the six months ending December 2025, signalling steady returns for shareholders.

Future Generation Global Limited has announced a fully franked special dividend of AUD 0.03 per share for the half-year ending December 2025, accompanied by a dividend reinvestment plan with no discount.

Apiam Animal Health Limited has announced a special fully franked dividend of AUD 0.10 per share, with payment scheduled for mid-February 2026. Notably, the company has suspended its dividend reinvestment plan for this payout.

Pinnacle Investment Management Group Limited has announced a fully franked ordinary dividend of AUD 0.29 per share for the half-year ending December 2025, with a dividend reinvestment plan available to shareholders.

Apiam Animal Health shareholders have predominantly elected to receive scrip or mixed consideration in the proposed acquisition, with a special dividend of 10 cents per share proposed pending scheme approval.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Renegade Exploration has reported significant progress across its North American and Australian mineral portfolios, highlighting high-grade gold, silver, and critical mineral results and planning a maiden drill program at its Yukon Myschka Project in 2026.